Literature DB >> 7057811

The effects of diltiazem in dystrophic hamsters.

S K Bhattacharya, G M Palmieri, T E Bertorini, D F Nutting.   

Abstract

Calcium accumulates in muscles of dystrophic hamsters (DH) and patients with Duchenne muscular dystrophy. Various Ca antagonists were beneficial to the cardiomyopathy of DH, but had only minor effects on skeletal muscle. We administered a new Ca antagonist, diltiazem, 25 mg/kg/day orally to normal and dystrophic hamsters from ages 37 to 92 days. We observed a marked reduction in muscle Ca in DH treated with diltiazem: 73% in the heart, 61% in the diaphragm, and 48% in the rectus femoris. Plasma CK was significantly lower (by 37%) in treated DH, while the elevated rate of noncollagen protein synthesis in the diaphragm was not diminished. Histologically, the most important change was a reduction in Ca deposits in the heart. Diltiazem was well-tolerated by all animals and did not modify Ca content in normal hamsters. This study suggests that diltiazem may have therapeutic value in those conditions that are accompanied by excessive accumulation of Ca in tissues, such as muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7057811     DOI: 10.1002/mus.880050114

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  Structure and function of the respiratory system of the dystrophic hamster.

Authors:  E H Schlenker; J A Burbach
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy.

Authors:  W Pernice; R Beckmann; U P Ketelsen; M Frey; B Schmidt-Redemann; K P Haap; R Roehren; M Sauer
Journal:  Klin Wochenschr       Date:  1988-07-01

Review 3.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

Review 4.  Cellular and molecular pathways to myocardial necrosis and replacement fibrosis.

Authors:  Malay S Gandhi; German Kamalov; Atta U Shahbaz; Syamal K Bhattacharya; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

Review 5.  Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies.

Authors:  Atta U Shahbaz; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling; Jesse E McGee; Karl T Weber
Journal:  J Hypertens       Date:  2010-09       Impact factor: 4.844

Review 6.  Mitochondria play a central role in nonischemic cardiomyocyte necrosis: common to acute and chronic stressor states.

Authors:  M Usman Khan; Yaser Cheema; Atta U Shahbaz; Robert A Ahokas; Yao Sun; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  Pflugers Arch       Date:  2012-02-11       Impact factor: 3.657

7.  Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice.

Authors:  O Friedrich; M Both; J M Gillis; J S Chamberlain; R H A Fink
Journal:  J Physiol       Date:  2003-10-31       Impact factor: 5.182

Review 8.  Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism.

Authors:  Syamal K Bhattacharya; Malay S Gandhi; German Kamalov; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

9.  Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism.

Authors:  German Kamalov; Robert A Ahokas; Wenyuan Zhao; Atta U Shahbaz; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-13       Impact factor: 4.733

10.  Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism.

Authors:  German Kamalov; Prajwal A Deshmukh; Narina Y Baburyan; Malay S Gandhi; Patti L Johnson; Robert A Ahokas; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2009-05       Impact factor: 3.105

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.